Nrf2 and Her3 co-expression in cholangiocarcinoma: Possible biological pathways for potential therapeutic approach

doi:10.1016/j.hbpd.2023.02.010

Abstract
Figure/Table
References (0)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Cholangiocarcinomas (CCAs) are heterogeneous group of malignancies, encompassing intrahepatic CCA (iCCA), and extrahepatic CCA (eCCA); they are also classified into common hepatic duct cholangiocarcinoma (CHDCCA), choledocus extrapancreatic cholangiocarcinoma (EPCCA) and choledocus intrapancreatic cholangiocarcinoma (IPCCA) and, finally, gallbladder carcinoma (GBCCA). CCAs are relatively uncommon but, over the past 15 years, the incidence has steadily increased worldwide. CCAs are highly aggressive neoplasms, characterized by poor clinical outcome. Since the majority of patients are diagnosed at advanced stages, only 10%-15% are suitable for potentially curative surgery [1].

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles in this journal by
	Parente P
	Angerilli V
	Zamboni G
	Sparaneo A
	Fiordelisi F
	Di Candia L
	Fassan M
	Graziano P

Cite this article:

Parente P, Angerilli V, Zamboni G, et al. Nrf2 and Her3 co-expression in cholangiocarcinoma: Possible biological pathways for potential therapeutic approach. Hepatobiliary Pancreat Dis Int 2024; 23(3): 317-321. DOI:10.1016/j.hbpd.2023.02.010

URL:

http://dx.doi.org/10.1016/j.hbpd.2023.02.010 OR http://www.hbpdint.com/EN/Y2024/V23/I3/317